Eurobio Scientific SA (ALERS) - Net Assets
Based on the latest financial reports, Eurobio Scientific SA (ALERS) has net assets worth €180.85 Million EUR (≈ $211.43 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€259.11 Million ≈ $302.92 Million USD) and total liabilities (€78.26 Million ≈ $91.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Eurobio Scientific SA's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €180.85 Million |
| % of Total Assets | 69.8% |
| Annual Growth Rate | 14.44% |
| 5-Year Change | 65.84% |
| 10-Year Change | 667.29% |
| Growth Volatility | 72.82 |
Eurobio Scientific SA - Net Assets Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA's net assets have evolved over time, based on quarterly financial data. Also explore Eurobio Scientific SA balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Eurobio Scientific SA (2007–2024)
The table below shows the annual net assets of Eurobio Scientific SA from 2007 to 2024. For live valuation and market cap data, see market cap of Eurobio Scientific SA.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €178.85 Million ≈ $209.10 Million |
+2.10% |
| 2023-12-31 | €175.17 Million ≈ $204.80 Million |
+1.45% |
| 2022-12-31 | €172.67 Million ≈ $201.87 Million |
+7.77% |
| 2021-12-31 | €160.22 Million ≈ $187.32 Million |
+48.57% |
| 2020-12-31 | €107.84 Million ≈ $126.08 Million |
+194.95% |
| 2019-12-31 | €36.56 Million ≈ $42.75 Million |
+23.44% |
| 2018-12-31 | €29.62 Million ≈ $34.63 Million |
-6.53% |
| 2017-12-31 | €31.69 Million ≈ $37.05 Million |
+159.23% |
| 2016-12-31 | €12.23 Million ≈ $14.29 Million |
-47.55% |
| 2015-12-31 | €23.31 Million ≈ $27.25 Million |
-16.60% |
| 2014-12-31 | €27.95 Million ≈ $32.67 Million |
+35.91% |
| 2013-12-31 | €20.56 Million ≈ $24.04 Million |
-16.07% |
| 2012-12-31 | €24.50 Million ≈ $28.64 Million |
+80.59% |
| 2011-12-31 | €13.57 Million ≈ $15.86 Million |
-29.31% |
| 2010-12-31 | €19.19 Million ≈ $22.44 Million |
-24.62% |
| 2009-12-31 | €25.46 Million ≈ $29.76 Million |
+161.40% |
| 2008-12-31 | €9.74 Million ≈ $11.39 Million |
-46.09% |
| 2007-12-31 | €18.07 Million ≈ $21.12 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Eurobio Scientific SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15522600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €155.23 Million | 86.79% |
| Common Stock | €3.28 Million | 1.83% |
| Other Comprehensive Income | €155.38 Million | 86.88% |
| Total Equity | €178.85 Million | 100.00% |
Eurobio Scientific SA Competitors by Market Cap
The table below lists competitors of Eurobio Scientific SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Honghua Group Limited
F:4HB
|
$236.20 Million |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
$236.24 Million |
|
Bank Yudha Bhakti Tbk
JK:BBYB
|
$236.25 Million |
|
Praemium Ltd
AU:PPS
|
$236.27 Million |
|
Activate Energy Acquisition Corp. Class A Ordinary Share
NASDAQ:AEAQ
|
$235.98 Million |
|
First National Corp
NASDAQ:FXNC
|
$235.92 Million |
|
Hyundai Cement
KO:006390
|
$235.90 Million |
|
Secuoya Grupo de Comunicación S.A
MC:SEC
|
$235.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eurobio Scientific SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 175,173,000 to 178,855,000, a change of 3,682,000 (2.1%).
- Net income of 4,000,000 contributed positively to equity growth.
- Share repurchases of 149,000 reduced equity.
- Other comprehensive income increased equity by 157,062,000.
- Other factors decreased equity by 157,231,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €4.00 Million | +2.24% |
| Share Repurchases | €149.00K | -0.08% |
| Other Comprehensive Income | €157.06 Million | +87.82% |
| Other Changes | €-157.23 Million | -87.91% |
| Total Change | €- | 2.10% |
Book Value vs Market Value Analysis
This analysis compares Eurobio Scientific SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.59x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | €14.13 | €22.50 | x |
| 2008-12-31 | €7.27 | €22.50 | x |
| 2009-12-31 | €18.10 | €22.50 | x |
| 2010-12-31 | €11.60 | €22.50 | x |
| 2011-12-31 | €4.03 | €22.50 | x |
| 2012-12-31 | €7.95 | €22.50 | x |
| 2013-12-31 | €7.23 | €22.50 | x |
| 2014-12-31 | €9.01 | €22.50 | x |
| 2015-12-31 | €6.56 | €22.50 | x |
| 2016-12-31 | €3.12 | €22.50 | x |
| 2017-12-31 | €3.61 | €22.50 | x |
| 2018-12-31 | €3.02 | €22.50 | x |
| 2019-12-31 | €3.25 | €22.50 | x |
| 2020-12-31 | €9.52 | €22.50 | x |
| 2021-12-31 | €14.70 | €22.50 | x |
| 2022-12-31 | €16.80 | €22.50 | x |
| 2023-12-31 | €15.62 | €22.50 | x |
| 2024-12-31 | €17.45 | €22.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eurobio Scientific SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.58%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.44x
- Recent ROE (2.24%) is above the historical average (-17.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -40.63% | -136.30% | 0.14x | 2.08x | €-9.15 Million |
| 2008 | -91.64% | -211.54% | 0.14x | 3.06x | €-9.90 Million |
| 2009 | -30.25% | -157.42% | 0.13x | 1.44x | €-10.25 Million |
| 2010 | -40.37% | -92.04% | 0.27x | 1.63x | €-9.67 Million |
| 2011 | -52.33% | -142.21% | 0.28x | 1.30x | €-8.46 Million |
| 2012 | -23.55% | -107.11% | 0.14x | 1.57x | €-8.22 Million |
| 2013 | -29.15% | -19.20% | 0.93x | 1.62x | €-8.05 Million |
| 2014 | -19.64% | -17.67% | 0.77x | 1.45x | €-8.28 Million |
| 2015 | -25.23% | -19.74% | 0.83x | 1.53x | €-8.21 Million |
| 2016 | -63.29% | -27.79% | 0.87x | 2.61x | €-8.95 Million |
| 2017 | -31.46% | -23.30% | 0.60x | 2.26x | €-13.14 Million |
| 2018 | -9.35% | -5.42% | 0.73x | 2.36x | €-5.73 Million |
| 2019 | 8.62% | 5.30% | 0.73x | 2.22x | €-503.40K |
| 2020 | 68.61% | 38.91% | 1.10x | 1.61x | €62.77 Million |
| 2021 | 37.86% | 32.78% | 0.88x | 1.31x | €44.55 Million |
| 2022 | 14.47% | 16.34% | 0.46x | 1.92x | €7.70 Million |
| 2023 | 2.76% | 3.70% | 0.41x | 1.81x | €-12.68 Million |
| 2024 | 2.24% | 2.58% | 0.60x | 1.44x | €-13.89 Million |
Industry Comparison
This section compares Eurobio Scientific SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $7,526,509
- Average return on equity (ROE) among peers: -55.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eurobio Scientific SA (ALERS) | €180.85 Million | -40.63% | 0.43x | $236.10 Million |
| Affluent Medical SAS (AFME) | $35.29 Million | -40.58% | 0.84x | $110.43 Million |
| Biosynex (ALBIO) | $-341.55K | 0.00% | 0.00x | $15.74 Million |
| Bluelinea SA (ALBLU) | $127.40K | -31.25% | 1.42x | $9.16 Million |
| Carmat (ALCAR) | $7.23 Million | -202.60% | 2.04x | $6.37 Million |
| Diagnostic Medical Systems SA (ALDMS) | $17.88 Million | -30.51% | 1.06x | $34.50 Million |
| Ikonisys SA (ALIKO) | $5.70 Million | -27.59% | 0.42x | $21.30 Million |
| Implanet SA (ALIMP) | $2.80 Million | -164.37% | 4.96x | $32.11 Million |
| Mediantechn (ALMDT) | $-11.36 Million | 0.00% | 0.00x | $200.33 Million |
| Mauna Kea Technologies SAS (ALMKT) | $10.41 Million | 0.00% | 0.39x | $28.43 Million |
About Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more